Tag: nasdaq:adms

September 20, 2019

Adamas Announces Data for GOCOVRI in Parkinson’s Disease

Adamas Pharmaceuticals (NASDAQ:ADMS) has announced presentation of new data on GOCOVRI to treat dyskinesia in patients with Parkinson’s disease. As...
September 12, 2019

5 Alzheimer’s Disease Treatment Stocks on the NASDAQ

A report from Reports and Data suggests the overall Alzheimer's market will be worth US$12.43 billion by 2026.
December 19, 2018

Adamas Announces Issuance of New U.S. Patent Covering GOCOVRI

Adamas Pharmaceuticals (Nasdaq:ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced that a new...
October 4, 2018

Adamas Announces Publication of Data Demonstrating Dyskinesia’s Impact on Activities of Daily Living in People with Parkinson’s Disease

Adamas Pharmaceuticals (Nasdaq:ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced that pooled...